• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

    5/14/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025.

    A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

    About Compass Pathways

    Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthesized psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

    Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250514227328/en/

    Enquiries

    Media: Dana Sultan-Rothman, [email protected], +1 484 432 0041

    Investors: Stephen Schultz, [email protected], +1 401 290 7324

    Get the next $CMPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    11/22/2021$100.00 → $120.00Buy
    HC Wainwright & Co.
    More analyst ratings